Moe Elbadawi

Dr. Moe Elbadawi


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2024 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
MEMoe Elbadawi
Moe Elbadawi
HLHanxiang Li
Hanxiang Li
ABAbdul W. Basit
Abdul W. Basit
Simon GaisfordSimon Gaisford
Simon Gaisford
Artificial intelligence (AI) is a revolutionary technology that is finding wide application across numerous sectors. Large language models (LLMs) are an emerging subset technology of AI and have been developed to communicate using human languages. At their core, LLMs are trained with vast amounts of information extracted from the internet, including text and images. Their ability to create human-like, expert text in almost any subject means they are increasingly being used as an aid to presentation, particularly in scientific writing. However, we wondered whether LLMs could go further, generating original scientific research and preparing the results for publication. We taskedGPT-4, an LLM, to write an original pharmaceutics manuscript, on a topic that is itself novel. It was able to conceive a research hypothesis, define an experimental protocol, produce photo-realistic images of 3D printed tablets, generate believable analytical data from a range of instruments and write a convincing publication-ready manuscript with evidence of critical interpretation. The model achieved all this is less than 1 h. Moreover, the generated data were multi-modal in nature, including thermal analyses, vibrational spectroscopy and dissolution testing, demonstrating multi-disciplinary expertise in the LLM. One area in which the model failed, however, was in referencing to the literature. Since the generated experimental results appeared believable though, we suggest that LLMs could certainly play a role in scientific research but with human input, interpretation and data validation. We discuss the potential benefits and current bottlenecks for realising this ambition here.

28 July 2025 in The AAPS Journal
Verified
Journal Article
Open access
CPChrystalla Protopapa
Chrystalla Protopapa
ASAngeliki Siamidi
Angeliki Siamidi
AEAmelia Adibe Eneli
Amelia Adibe Eneli
MEMoe Elbadawi
Moe Elbadawi
MVMarilena Vlachou
Marilena Vlachou
Direct compression (DC) remains a popular manufacturing technology for producing solid dosage forms. However, the formulation optimisation is a laborious process, costly and time-consuming. The aim of this study was to determine whether machine learning (ML) can be used to accelerate developments by predicting the drug release profiles under dynamic conditions given the composition of formulations. A total of 377 formulations were produced in-house and their release profile under dynamic dissolution conditions was measured from 0 to 480 min across 11 time points. A subsequent ML analysis involved predicting the entire release profile. Six different ML techniques were explored, where random forest (RF) and extreme gradient boosting (XGB) were found to achieve a fivefold cross-validation R2 of 0.635 ± 0.047 and 0.601 ± 0.091, respectively. A second ML strategy was developed, where the ML techniques predict the kinetic parameters of the Weibull and a modified first-order kinetic release model and subsequently use the predicted parameters to fit the release profiles. The R2 results using RF were comparable to the first strategy. These findings demonstrate that ML can be used to predict entire drug release profiles during dynamic dissolution studies, whilst simultaneously providing insight into kinetic parameters, thus making the modelling process more informative for pharmaceutical researchers. Future work will seek to investigate more ‘kinetic-informed’ ML models. Graphical Abstract

30 October 2023 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
HLHanxiang Li
Hanxiang Li
MAManal E. Alkahtani
Manal E. Alkahtani
ABAbdul W. Basit
Abdul W. Basit
MEMoe Elbadawi
Moe Elbadawi
Simon GaisfordSimon Gaisford
Simon Gaisford
3D Printing (3DP) of pharmaceuticals could drastically transform the manufacturing of medicines and facilitate the widespread availability of personalised healthcare. However, with increasing awareness of the environmental damage of manufacturing, 3DP must be eco-friendly, especially when it comes to carbon emissions. This study investigated the environmental effects of pharmaceutical 3DP. Using Design of Experiments (DoE) and Machine Learning (ML), we looked at energy use in pharmaceutical Fused Deposition Modeling (FDM). From 136 experimental runs across four common dosage forms, we identified several key parameters that contributed to energy consumption, and consequently CO2 emission. These parameters, identified by both DoE and ML, were the number of objects printed, build plate temperature, nozzle temperature, and layer height. Our analysis revealed that minimizing trial-and-error by being more efficient in R&D and reducing the build plate temperature can significantly decrease CO2 emissions. Furthermore, we demonstrated that only the ML pipeline could accurately predict CO2 emissions, suggesting ML could be a powerful tool in in the development of more sustainable manufacturing processes. The models were validated experimentally on new dosage forms of varying geometric complexities and were found to maintain high accuracy across all three dosage forms. The study underscores the potential of merging sustainability and digitalization in the pharmaceutical sector, aligning with the principles of Industry 5.0. It highlights the comparable learning traits between DoE and ML, indicating a promising pathway for wider adoption of ML in pharmaceutical manufacturing. Through focused efforts to reduce wasteful practices and optimize printing parameters, we can pave the way for a more environmentally sustainable future in pharmaceutical 3DP.

16 November 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SSSiyuan Sun
Siyuan Sun
MAManal E. Alkahtani
Manal E. Alkahtani
Simon GaisfordSimon Gaisford
Simon Gaisford
ABAbdul W Basit
Abdul W Basit
MEMoe Elbadawi
Moe Elbadawi
Mine OrluMine Orlu
Mine Orlu
Three-dimensional (3D) printing is an advanced pharmaceutical manufacturing technology, and concerted efforts are underway to establish its applicability to various industries. However, for any technology to achieve widespread adoption, robustness and reliability are critical factors. Machine vision (MV), a subset of artificial intelligence (AI), has emerged as a powerful tool to replace human inspection with unprecedented speed and accuracy. Previous studies have demonstrated the potential of MV in pharmaceutical processes. However, training models using real images proves to be both costly and time consuming. In this study, we present an alternative approach, where synthetic images were used to train models to classify the quality of dosage forms. We generated 200 photorealistic virtual images that replicated 3D-printed dosage forms, where seven machine learning techniques (MLTs) were used to perform image classification. By exploring various MV pipelines, including image resizing and transformation, we achieved remarkable classification accuracies of 80.8%, 74.3%, and 75.5% for capsules, tablets, and films, respectively, for classifying stereolithography (SLA)-printed dosage forms. Additionally, we subjected the MLTs to rigorous stress tests, evaluating their scalability to classify over 3000 images and their ability to handle irrelevant images, where accuracies of 66.5% (capsules), 72.0% (tablets), and 70.9% (films) were obtained. Moreover, model confidence was also measured, and Brier scores ranged from 0.20 to 0.40. Our results demonstrate promising proof of concept that virtual images exhibit great potential for image classification of SLA-printed dosage forms. By using photorealistic virtual images, which are faster and cheaper to generate, we pave the way for accelerated, reliable, and sustainable AI model development to enhance the quality control of 3D-printed medicines.

20 November 2025 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
OUOlima Uddin
Olima Uddin
YMYusuf Ali Mohammed
Yusuf Ali Mohammed
SGSimon Gaisford
Simon Gaisford
MEMoe Elbadawi
Moe Elbadawi

24 February 2026 in Drug Delivery and Translational Research
Verified
Journal Article
Open access
PDF file
MEMoe Elbadawi
Moe Elbadawi
NKNoorul Fathima Abdul Kafoor
Noorul Fathima Abdul Kafoor
HLHanxiang Li
Hanxiang Li
CPChrystalla Protopapa
Chrystalla Protopapa
MVMarilena Vlachou
Marilena Vlachou
SGSimon Gaisford
Simon Gaisford
Machine learning (ML) is expected to accelerate the developments of three-dimensional (3D) printed medicines. Despite ML’s potential, the need for large datasets can hinder progression, as 3D printing remains an emerging pharmaceutical manufacturing technology. This study explores an ML strategy called active learning (AL), which harnesses the benefits of ML whilst applicable with small datasets. AL was tested to predict the printability of three 3D printing datasets: 1437 fused deposition modelling (FDM), 650 vat polymerisation and 297 selective laser sintering (SLS) formulations. The analysis revealed that accuracies of 60% can be achieved when starting with 33 formulations, and subsequent increases in training data size enhances predictive performance. Furthermore, AL was found to achieve 100% predictive accuracy, which is the highest recorded to date for pharmaceutical 3D printing. These initial findings highlight AL’s advantages over traditional ML modelling and showcase its potential to accelerate the development of 3D printing medicines. This research also demonstrates the potential of modelling with small datasets, thereby widening ML’s application in pharmaceutical research. Graphical abstract